CHMA News and Press, Chiasma Inc. From 03/02/21

NEEDHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company, today announced that management will present a company overview at the H.C. Wainwright Global Life Sciences Conference, which is being held Tuesday, March 9 th ...

NEEDHAM, Maine, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Thursday, March 4, 2021 at 5:00 pm Eastern Time to discuss financial results for the qu...

CHMA's MYCAPSSA was approved and launched last year for acromegaly. MYCAPSSA is an oral formulation of a well-known injection. The market potential runs into hundreds of millions of dollars, and yet, the stock seems depressed. For further details see: Chiasma: Undervalue...

The move is effective today.Most recently, Mr. Doyle served as Vice President of Finance and Investor Relations at Verastem.Mark Fitzpatrick, Chiasma’s (CHMA) current President and Principal Financial Officer, will remain with the company in a consulting role through June 30, 2021...

NEEDHAM, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burd...

Chiasma (CHMA) says that it is on track to file European marketing approval for Mycapssa (octreotide) in mid-2021, which was approved by the FDA in June last year.For U.S interim Mycapssa net revenues for 2020 are expected to be between $0.9M - $1.1M.Reported positive data OPTI...

MYCAPSSA ® launch in US continuing to gain traction with physicians, patients, and payers MYCAPSSA ® EMA submission for EU marketing approval on track for mid-2021 following positive results of MPOWERED Phase 3 clinical trial NEEDHAM, Mass., Jan. 06, ...

Gainers: [[CNFR]] +90.6%. [[IMMP]] +8.5%. [[NGL]] +4.4%. [[CHMA]] +3.8%. [[MDU]] +3.6%.Losers: [[JRJC]] -10.0%. [[GBR]] -7.4%. [[ACY]] -6.4%. [[EQ]] -4.5%. [[IRIX]] -4.1%. For further details see: CNFR, ACY, IMMP, and JRJC among after-hours movers

Chiasma launched its first product, Mycapssa, on August 31, 2020. Mycapssa is the first product utilizing Chiasma's proprietary technology platform that enables oral version of previously injection-only therapies by transiently enhancing intestinal permeability. Chiasma is well-fu...

Tredegar Corporation (TG +29% on declaring special dividend.Catabasis Pharmaceuticals (CATB) +25%.India Globalization Capital (IGC) +19%.Ashford Hospitality Trust (AHT) +14%.Mesoblast Limited (MESO) +12%.iBio (IBIO +12% after company was selected to produce ATB Therapeutic...